Dr. Yuhchyau Chen
Claim this profileUniversity of Rochester
Expert in Parotid Gland Cancer
Studies Lung Cancer
38 reported clinical trials
81 drugs studied
About Yuhchyau Chen
Education:
- MD from the University of Rochester School of Medicine and Dentistry, 1997.
Experience:
- Completed Residency in Internal Medicine at the University of Rochester Medical Center, 2000.
- Finished Fellowship in Hematology/Oncology at the University of Rochester Medical Center, 2003.
- Currently an Associate Professor of Medicine at the University of Rochester Medical Center, with a specialization in Hematology and Oncology.
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage II
Stage III
2Lung Cancer
Stage II
Stage I
Stage IV
Affiliated Hospitals
Clinical Trials Yuhchyau Chen is currently running
Surgery and Radiation vs. Radiation Alone
for Brain Cancer
This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation to target tumors and minimizes effect on normal surrounding brain tissue. The combination of surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases. This study investigates whether treating with SRS before surgery may be better than SRS after surgery in reducing the possibility of the tumor coming back, reducing or preventing the cancer from spreading to other areas of the brain and reducing the risk of scarring on the brain from radiation.
Recruiting2 awards Phase 3
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
More about Yuhchyau Chen
Clinical Trial Related6 years of experience running clinical trials · Led 38 trials as a Principal Investigator · 21 Active Clinical TrialsTreatments Yuhchyau Chen has experience with
- Radiation Therapy
- Cisplatin
- Intensity-Modulated Radiation Therapy
- Paclitaxel
- Carboplatin
- Atezolizumab
Breakdown of trials Yuhchyau Chen has run
Parotid Gland Cancer
Lung Cancer
Prostate Cancer
Prostate Adenocarcinoma
Prostatic Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Yuhchyau Chen specialize in?
Is Yuhchyau Chen currently recruiting for clinical trials?
Are there any treatments that Yuhchyau Chen has studied deeply?
What is the best way to schedule an appointment with Yuhchyau Chen?
What is the office address of Yuhchyau Chen?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.